Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Condition:   Head and Neck Squamous Cell Carcinoma
Interventions:   Drug: Ramucirumab;   Drug: Pembrolizumab;   Other: EORTC QLQ-30;   Other: FACT H&N;   Procedure: Peripheral blood
Sponsors:   Washington University School of Medicine;   Eli Lilly and Company
Not yet recruiting

https://ift.tt/2NuYeVd